Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obese adults: a phase 2 trial
Lethargy or fatigue : Some users report temporary tiredness, particularly in the first few days
Delayed gastric emptying, heaviness after meals 812%
63 This natural drug shows great therapeutic potential owing to its dual antiproliferative and apoptosis-inducing effects, its anti-inflammatory effect also suggests its potential to sensitize high-inflammatory cells to radiotherapy, which highlights its promise in osteosarcoma radiotherapy treatment
submit false information
US$ 21.18
US$ 22.43
US$ 29.03
